Circulating Tumor DNA in Lung Cancer: Real-Time Monitoring of Disease Evolution and Treatment Response
Lung cancer remains one of the leading causes of cancer-related deaths worldwide. Despite advancements in diagnostic and therapeutic strategies, the prognosis for patients with advanced or metastatic lung cancer remains poor. Circulating tumor DNA (ctDNA), a component of cell-free DNA (cfDNA) released from apoptotic and necrotic tumor cells, has emerged as a powerful tool for non-invasive real-time monitoring of lung cancer. This review explores the biology of ctDNA, technological advancements in its detection, and its clinical applications in both non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).
Biology of ctDNA: Release and Clearance
ctDNA is primarily released into the bloodstream as ~166-base pair double-stranded DNA fragments from apoptotic and necrotic tumor cells. It can also be actively secreted by tumor cells, as demonstrated by DNA electrophoresis studies. In addition to ctDNA, other components such as circulating tumor cells (CTCs), circulating exosomes, and blood platelets are also candidates for liquid biopsy. The median half-life of ctDNA in NSCLC is approximately 35 minutes, making it suitable for real-time monitoring of disease progression. ctDNA levels are generally lower than those of cfDNA, posing challenges for sensitive detection. However, ctDNA can be detected not only in plasma but also in cerebrospinal fluid, sputum, and pleural fluids, offering multiple sources for genomic analysis.
The clearance of cfDNA occurs in organs such as the kidney, liver, spleen, and lymph nodes. In malignant diseases, the balance between DNA release and clearance is disrupted, leading to the accumulation of cfDNA. This accumulation is attributed to the increased rate of cell death and dysfunction in the clearance system. Interestingly, ctDNA can enter tissue cells and influence their biological behavior, as demonstrated by studies showing that plasma from colorectal cancer patients can transform mouse cell lines. This suggests that ctDNA may play an active role in tumorigenesis and metastasis.
Technological Advances in ctDNA Detection
The detection of ctDNA has evolved significantly, with techniques now offering high sensitivity and specificity. These methods can be broadly categorized into targeted and untargeted technologies. Targeted methods focus on detecting mutations in predefined gene panels, while untargeted methods aim to identify genomic alterations across exomes or the entire genome. Digital polymerase chain reaction (dPCR) and next-generation sequencing (NGS) are among the most widely used techniques, with sensitivities ranging from 74% to 100% and specificities from 63% to 100%.
PCR-based assays are particularly useful for detecting recurrent point mutations in driver genes such as EGFR and KRAS. NGS, on the other hand, allows for the identification of somatic mutations and copy number alterations (CNAs) in ctDNA, providing a comprehensive view of the tumor genome. However, NGS faces limitations such as low sensitivity, high cost, and the need for optimization for individual patients. To address these challenges, novel approaches like cancer personalized profiling by deep sequencing (CAPP-Seq) have been developed. CAPP-Seq achieves a sensitivity of 100% in stage II-IV NSCLC patients and 50% in stage I patients, making it a promising tool for early cancer detection.
Applications of ctDNA in NSCLC
Screening and Early Diagnosis
The presence of ctDNA in the blood makes it a valuable tool for the early detection of lung cancer. Compared to traditional radiographic methods and blood protein biomarkers, ctDNA provides a direct measurement of tumor genomic alterations. Early diagnosis allows for timely clinical intervention, potentially improving patient outcomes. However, the sensitivity of ctDNA detection varies with disease stage, with sensitivities of 82% for stage IV disease and 47% for stage I disease. Techniques such as NGS and droplet digital PCR (ddPCR) have shown higher sensitivity and reliability in detecting EGFR mutations in early-stage NSCLC patients, offering a non-invasive alternative to tissue biopsies.
Prognosis Prediction, Staging, and Patient Stratification
Elevated levels of cfDNA and ctDNA are associated with tumor progression in lung cancer patients. The presence of ctDNA mutations, particularly in the EGFR gene, has been linked to poor prognosis. For example, patients with ctDNA EGFR mutations have been shown to have shorter progression-free survival (PFS) and overall survival (OS) compared to those without these mutations. However, some studies have reported conflicting results, highlighting the need for standardized patient selection and therapeutic regimens.
Structural alterations and epigenetic markers in ctDNA also play a role in prognosis prediction. Copy number alterations (CNAs) and genome-wide hypermethylation have been identified as prognostic factors in NSCLC. The detection of cancer-specific methylation patterns in ctDNA or sputum offers a non-invasive method for identifying epigenetic biomarkers associated with treatment response and prognosis.
Non-Invasive Profiling of Genomic Characteristics
ctDNA analysis allows for the non-invasive profiling of genomic characteristics, including mutation status and structural variants. The detection of EGFR mutations in ctDNA has shown high sensitivity and specificity, making it a valuable tool for selecting patients for targeted therapies. For instance, the T790M EGFR mutation, which confers resistance to first-generation EGFR tyrosine kinase inhibitors (TKIs), can be detected in ctDNA, guiding the use of third-generation TKIs.
CNAs and chromosomal rearrangements can also be detected in ctDNA using whole-genome sequencing (WGS) and hybrid-capture approaches. These structural alterations are clinically relevant, as they often serve as targets for therapy. However, accurate CNA assessment requires a higher concentration of ctDNA in plasma, typically with a variant allele fraction (AF) of at least 5%.
Minimal Residual Disease (MRD) and Relapse
ctDNA detection is highly specific for identifying minimal residual disease (MRD) and predicting the likelihood of relapse. Studies have shown that ctDNA can precede radiological imaging in detecting disease recurrence by a median of 5.2 months. The optimal timing for ctDNA detection after surgery is crucial, with post-operative ctDNA profiling on day 3 and day 30 being predictive of unfavorable relapse-free survival (RFS) and OS.
Blood Tumor Mutational Burden (bTMB) and Immunotherapy
High tumor mutational burden (TMB) is a marker of genomic instability and is associated with a better response to immune checkpoint blockade therapy. Blood TMB (bTMB), measured using ctDNA, has emerged as a predictive biomarker for immunotherapy in NSCLC. Patients with higher bTMB levels have shown superior PFS and are more likely to benefit from immune checkpoint inhibitors such as atezolizumab, durvalumab, and tremelimumab.
Tumor Evolution, Clonal Selection, and Heterogeneity
The concept of tumor evolution provides insights into the mechanisms of resistance, progression, and metastasis. ctDNA sequencing, combined with multi-region tumor whole-exome sequencing, allows for the tracking of tumor evolution and the identification of clonal and subclonal populations. The Lung TRACERx study, for example, used phylogenetic trees to depict the evolutionary histories of lung cancer patients, revealing the clonal nature of driver alterations and the heterogeneity of subclones. This approach enables the identification of emerging subclones that may contribute to relapse and resistance, guiding targeted interventions.
Applications of ctDNA in SCLC
SCLC is characterized by a high somatic tumor mutation burden, primarily due to its association with tobacco carcinogens. Common genetic alterations in SCLC include the inactivation of tumor suppressor genes such as TP53 and RB1, as well as point mutations in genes related to chromatin remodeling and receptor tyrosine kinases. Despite the genomic complexity of SCLC, ctDNA detection has shown promise in identifying mutations associated with the disease. Studies have reported mutation frequencies in SCLC-associated genes ranging from 0.1% to 87%, with TP53 and RB1 being the most commonly mutated genes.
ctDNA dynamics in SCLC patients have been shown to correlate with treatment responses, and post-operative ctDNA detection can predict disease relapse before it is detectable by imaging. However, the chaotic genomic background of SCLC poses challenges for ctDNA detection, necessitating further research and technological advancements.
Conclusion and Perspectives
ctDNA has proven to be a valuable tool in the screening, diagnosis, and monitoring of lung cancer. Its applications extend from early detection and prognosis prediction to the identification of minimal residual disease and the tracking of tumor evolution. Despite the challenges associated with sensitivity, specificity, and standardization, ctDNA analysis offers a non-invasive and real-time approach to personalized cancer care. Future research should focus on improving detection techniques, expanding the use of ctDNA in SCLC, and integrating ctDNA analysis into clinical practice to enhance patient outcomes.
doi.org/10.1097/CM9.0000000000001097
Was this helpful?
0 / 0